Source Post

Novo Nordisk ($NVO) vs Eli Lilly ($LLY) And Super Micro Computer ($SMCI) Drama

Mar 21, 2026

The creator discusses Novo Nordisk and Eli Lilly, focusing on their competition in the GLP-1 and oral weight loss markets. The creator also touches on Super Micro Computer and an alleged scheme involving Nvidia chips.

Linked Mentions

Tickers discussed in this post

ZETABullishHigh ConvictionSignal-backedPrimary

Zeta is a stock the creator loves and is willing to average up on.

ELFBullishMedium ConvictionSignal-backedSecondary

ELF is a buying opportunity on the current dip.

NOWBullishMedium ConvictionSignal-backedSecondary

Service Now is a buying opportunity on the current dip.

DUOLNeutralLow ConvictionSignal-backedSecondary

The creator is hesitant to average down on Duolingo despite its dip, preferring other stocks.

PYPLBullishMedium ConvictionSignal-backedSecondary

PayPal has upside potential if acquired, with a potential buyout price of $65-$70 per share.

MSFTBullishMedium ConvictionSignal-backedSecondary

Microsoft is a good buy at $380, with the creator having purchased shares in multiple portfolios.

OSCRBullishHigh ConvictionSignal-backedPrimary

Oscar Health is a strong buy with a $30 price target by 2026, despite current market weakness.

NVDANeutralLow ConvictionResearch Only

Nvidia chips are mentioned as part of an alleged scheme involving Super Micro Computer.

SMCINeutralLow ConvictionSignal-backedSecondary

Super Micro Computer is mentioned in the context of alleged schemes involving Nvidia chips.

LLYNeutralMedium ConvictionSignal-backedSecondary

Eli Lilly's delayed FDA decision for its oral pill creates an opportunity for Novo Nordisk.

Linked Signals

Tracked calls opened from this post

OSCR
buy opened Mar 21, 2026
+130.40%
NVO
buy opened Mar 21, 2026
+37.75%
ZETA
buy opened Mar 21, 2026
+27.91%